Natera Reports 37.7% Revenue Growth and Reduced Net Loss in Latest Quarter

Natera, Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $752.8 million, a 37.7% increase from $546.6 million in the same period last year. Product revenues, which primarily stem from the sales of its genetic tests, rose to $747.9 million, up from $544.4 million, reflecting a 37.4% growth. The net loss for the quarter was $66.9 million, a notable reduction from a loss of $100.9 million in the prior year, indicating a 33.7% improvement in profitability.

In terms of operational metrics, Natera processed approximately 985,500 tests during the quarter, compared to 812,900 tests in the same quarter of 2025, marking a 21.2% increase. The growth in test volume was driven by the continued commercial success of its key products, including Signatera, Panorama, and Horizon. The average selling price (ASP) of tests also improved, increasing by approximately 13.3% year-over-year, attributed to a higher proportion of revenues from Signatera, which commands a premium price.

Strategically, Natera completed the acquisition of Foresight Diagnostics in December 2025, which has expanded its capabilities in molecular residual disease detection. The acquisition was valued at $424.5 million and included the issuance of shares and contingent consideration based on performance milestones. This acquisition is expected to enhance Natera's product offerings and market position in oncology diagnostics. The company also reported an increase in its employee headcount, reflecting its ongoing investment in research and development, which rose by 59.3% to $438.8 million for the six months ended June 30, 2026.

Geographically, the majority of Natera's revenues continue to come from the United States, accounting for approximately 95% of total revenues, with international sales contributing around 2%. The company is focused on expanding its market share and increasing reimbursement rates for its tests, particularly for Signatera, which is not yet widely reimbursed by third-party payers. Natera's cash position remains strong, with $1.1 billion in cash and cash equivalents as of June 30, 2026, although it continues to incur net losses and anticipates the need for additional financing to support its growth initiatives.

Looking ahead, Natera aims to leverage its recent acquisitions and product innovations to drive revenue growth and improve profitability. The company expects to continue investing in its research and development efforts while seeking to enhance its reimbursement landscape. However, it acknowledges the potential need for additional equity or debt financing to support its operations and growth strategies in the future.